-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
Fabrice Barlesi, MD
Posted: June 2018 The 2018 Heine H. Hansen Award recipient was IASLC Lung Cancer News Associate Editor Fabrice Barlesi, MD. The award was presented at the 2018 European Lung Cancer Congress (ELCC), sponsored by the European Society for Medical Oncology (ESMO) and the IASLC. Dr. Barlesi is professor of medicine at the University of Aix…
-
Managing Medication Shortages of Life-Saving Oncologic Therapeutics
Natural disasters, such as Hurricane Maria, may have contributed to more acute shortages than previously experienced. By Jorge Garcia, PharmD, MS, MHA, MBA, and Dina B. Dumercy, PharmD, BCOP, BCPS Posted: June 2018 Drug shortages in oncology date back to the late 1980s, when there was a scarcity of paclitaxel. Since then, with an increase…
-
FDA Fosters Understanding about Approval Process for Biosimilars
By Leah Christl, PhD, Associate Director for Therapeutic Biologics and Director of the Therapeutic Biologics and Biosimilars Staff, Center for Drug Evaluation and Research, FDA Posted: June 2018 All FDA-approved biologics, including reference and biosimilar products, undergo a thorough evaluation so that patients can be assured of the efficacy, safety, and quality of these products.…
-
Breaking News Briefs
New Lung Cancer Screening Guidelines Will Save Lives Reaction was swift and positive last week to new draft guidelines from the U.S. Preventive Services Task Force lowering the requirements for low dose CT imaging as a screening tool for those at risk for lung cancer. Current recommendations call for low-dose CT scans for 55- to…
-
European Perspective on ALCHEMIST
By Tiziana Vavalà, MD, andSilvia Novello, MD, PhD Posted: April 2018 Approximately 1.8 million new lung cancer cases worldwide are diagnosed annually, and 85% of these cases are NSCLC. Only 25% to 30% of patients with NSCLC are suitable for potentially curative resection. Despite optimal surgical management and postoperative treatments, nearly one-third of patients with…
-
Keeping It Personal: CMS-Proposed Coverage Restrictions for NGS Challenge Innovation in Personalized Care
By Jason N. Rosenbaum, MD, andDara L. Aisner, MD, PhD Posted: April 2018 Within the span of a few weeks, the U.S. Food and Drug Administration (FDA), the Center for Medicare and Medicaid Services (CMS), and the IASLC all issued guidelines, recommendations, or regulatory policy statements aimed at optimizing molecular testing for cancer.1-3 All three…
-
Q&A with the New IASLC President
Posted: February 2018 Giorgio Vittorio Scagliotti, MD, Professor of Oncology at University of Torino and Head of the Department of Oncology and Chief of the Division of Medical Oncology at the San Luigi Hospital in Torino, Italy, earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine, and medical oncology at…
-
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who are treatment naive who do not have a driver mutation and who have a high PD-L1 expression (≥50% tumor proportion score), frontline pembrolizumab is the accepted standard…
-
The Upcoming Lung Cancer Neoadjuvant Meeting
(Photo: Gideon Blumenthal, MD, Nicole Drezner, MD, Mark G. Kris, MD) By Erik J. MacLaren, PhD Posted: February 2018 The development of immunotherapies and targeted therapies for use in lung cancers has provided less-toxic options for treating these malignancies. Researchers have begun investigating the possibility of using these newer drugs in the neoadjuvant setting, that is,…
-
Inaugural Africa Conference: Finding Parallels Among Disparate Realities
New collaborative meeting to provide educational, scientific updates to diverse audience from Africa and the Middle East. By Joy Curzio, ILCN Managing Editor Posted: February 2018 As a global association, the IASLC understands the numerous variables, experiences, and perspectives that dictate a country’s or region’s ability to be a principal actor in scientific events. For…
View ILCN Archives
Provider Resources
Popular Articles